Gestational age at COVID-19 vaccination affects baby’s antibodies
The higher the gestational age when pregnant women received a COVID-19 vaccine, the higher the serological titers at birth.
Pregnant women and their newborns are at increased risk of severe or fatal COVID-19 disease. To prevent this, the US Centers for Disease Control and Prevention (CDC) advises expecting mothers to receive a COVID-19 vaccine. There has been a great deal of research establishing that COVID-19 vaccination is safe and effective for pregnant women and their unborn babies.
However, there has not been extensive research on how COVID-19 vaccination during different gestational periods affects autoimmune response. One study, presented during this week’s 40th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID), analyzed whether there was a correlation between gestational age at vaccination and antibody titer at birth.
The investigators recruited 84 new mothers at the Niguarda Hospital of Milan, Italy from May-November 2021. While pregnant, the women had received either the Pfizer-BioNTech or Moderna mRNA COVID-19 vaccine. Of the 84 women, 62 received 2 vaccine doses, while 22 just received 1 dose.
To evaluate serological IgG antibodies anti-S1 RBD, the investigators collected blood samples from the mothers and babies. They also gathered information about the type and timing of COVID-19 vaccination.
Among women who received 1 vaccine dose, the geometric mean titer (GMT) of anti-S IgG was 571.8 (7.4) AU/ml for the mothers and 329.2 (7.6) AU/ml for their babies. Of the mothers who received 2 doses of a COVID-19 vaccine, GMT was 5480.5 AU/ml for mothers and 6271.7 AU/ml for their babies.
Among the mothers who received 2 vaccine doses, the higher the gestational age at last vaccination, the higher the serological titers of the infants at birth.
The investigators concluded that mothers who received 2 doses of an mRNA vaccine passed antibody titer equal to or higher than their own to their babies.
These results imply that expecting mothers wishing to protect their newborns against COVID-19 infection may want to consider getting vaccinated later in their pregnancy.
This study, “Antibody Response Evaluation in SARS-CoV-2 Immunized Mothers and Babies at Birth,” was presented during the 40th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID), held online and in Athens, Greece from May 9-13, 2022.
Originally published on our sister brand, ContagionLive.
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
Cesarean delivery reduces mortality risk in preterm breech births
December 2nd 2024In a recent study, infants born very preterm or extremely preterm had reduced odds of mortality when cesarean delivery was chosen as the mode of delivery, without a notable increase in any morbidity risk.
Read More
Major congenital malformations not linked to first trimester tetracycline use
November 20th 2024A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.
Read More
No link found between prenatal cannabis use and childhood developmental delay
November 5th 2024In a recent study, offspring of women with cannabis use in early pregnancy confirmed by self-report or toxicology test were not at an increased risk of childhood early developmental delay up to the age of 5.5 years.
Read More
